ArticleCancer medicine2023

Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.

Ju Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.